Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Pilot Study of Pembrolizumab Treatment for Disease Relapse After Allogeneic Stem Cell Transplantation

NCT02981914 is registered in ClinicalTrials.gov with University of Chicago as lead sponsor.

NCT NCT02981914
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02981914 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Pilot Study of Pembrolizumab Treatment for Disease Relapse After Allogeneic Stem Cell Transplantation
Lead sponsor
University of Chicago
Phase
Phase 1
Overall status
Completed
Start date
March 7, 2017
Completion date
November 1, 2020
Enrollment
12 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

acute myeloid leukemia, b-cell non-hodgkin lymphoma, classical hodgkin lymphoma, myelodysplastic syndromes